	US 12,247,084 B2
	Anti-BCMA CAR antibodies, conjugates, and methods of use
Kevin Friedman, Melrose, MA (US); and Molly Reed Perkins, Milton, MA (US)
Assigned to 2seventy bio, Inc., Cambridge, MA (US)
Appl. No. 16/973,877
Filed by 2seventy bio, Inc., Cambridge, MA (US)
PCT Filed Jun. 14, 2019, PCT No. PCT/US2019/037274 § 371(c)(1), (2) Date Dec. 10, 2020, PCT Pub. No. WO2019/241686, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/685,043, filed on Jun. 14, 2018.
Prior Publication US 2021/0261689 A1, Aug. 26, 2021
Int. Cl. C07K 16/42 (2006.01); A61K 39/00 (2006.01); G01N 33/569 (2006.01); G01N 33/58 (2006.01); G01N 33/533 (2006.01); G01N 33/563 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/4258 (2013.01) [C07K 16/4241 (2013.01); G01N 33/56972 (2013.01); G01N 33/583 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); G01N 2333/70578 (2013.01)]

14 Claims

1. An antibody or antigen binding fragment thereof that binds an anti-BCMA scFv domain of an anti-BCMA CAR comprising a variable light chain comprising CDRL1-CDRL3 sequences set forth in SEQ ID NOs: 1-3 or 9-11; and a variable heavy chain comprising CDRH1-CDRH3 sequences set forth in SEQ ID NOs: 4-6 or 12-14.